Wyeth-Ayerst Pharmaceuticals Partners with Fox Chase Cancer Center: Cancer Risk Assessments Offered Free to Employees
PHILADELPHIA (September 29, 2000) -- Wyeth-Ayerst Pharmaceuticals of Radnor, Pa. and Fox Chase Cancer Center have teamed up to battle cancer with a work-site program, which includes cancer risk assessments for employees and their spouses.� The Pennsylvania Department of Health is funding this risk assessment program with a $1.5 million grant.
Wyeth-Ayerst Pharmaceuticals is one of six Pennsylvania employers selected to participate in the three-year grant which offers annual confidential cancer risk surveys completed on a voluntary basis by Wyeth-Ayerst employees and their spouses working in Pennsylvania.� Those who participate will receive a confidential individual report that will include a personalized risk assessment with specific suggestions for decreasing their risk of cancer.
Wyeth-Ayerst plans to use the annual aggregate information from Fox Chase's study to enhance their work-site cancer screening programs.� These health initiatives may include customized work-site educational and screening programs for preventing and detecting prostate, breast, colorectal, lung, and skin cancer.� The convenience of workplace screening often leads to greater participation and enhanced opportunity for early detection of cancer.
"The purpose of this project is to learn if employers can help reduce the burden of cancer and lower medical costs by helping their employees detect cancer early when it is most curable," said Dr. Paul F. Engstrom, senior vice president for population studies at Fox Chase.� "This type of partnership shows the dedication Wyeth-Ayerst has for the health and well-being of its employees."
Breast cancer screening takes place in a fully accredited mobile mammography van owned and staffed by Fox Chase Cancer Center.� Screening for prostate cancer is conducted by a Fox Chase oncologist and clinical staff which includes a physical examination and a blood sample for a PSA (prostate-specific antigen) test.� Skin cancer screening is performed in accordance with the American Academy of Dermatology guidelines.
Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE:AHP), is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular therapies, central nervous system drugs, anti-inflammatory agents, infectious disease, hemophilia, oncology, vaccines, and generic pharmaceuticals.� American Home Products Corporation (NYSE:AHP) is one of the world's largest research-based pharmaceutical and health care products companies.� It is a leader in the discovery, development, manufacturing and marketing of prescription drugs and over-the-counter medications.� It is also a leader in vaccines, biotechnology, and animal health care.
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.